AN2 Therapeutics (ANTX) EBIT (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly EBIT of -$10.6 million for Q1 2026, up 8.55% year-over-year from -$9.7 million in Q1 2025, and down 13.26% quarter-over-quarter from -$9.3 million in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) EBIT (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported EBIT for 6 consecutive years, with -$10.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 8.55% year-over-year to -$10.6 million; the TTM figure through Mar 2026 stood at -$37.1 million (up 25.8% YoY), while the FY2025 annual figure was -$38.1 million, up 32.89% from the prior year.
- EBIT retreated to -$10.6 million in Q1 2026 per ANTX's latest filing, from -$9.3 million in the prior quarter.
- Across five years, EBIT topped out at -$7.2 million in Q2 2025 and bottomed at -$18.8 million in Q4 2023.
- Historically, EBIT has averaged -$12.8 million across 5 years, with a median of -$11.8 million in 2022.
- Annual changes were most pronounced in 2022 — EBIT plunged 274.78% — and 2025, when it surged 54.56%.
- AN2 Therapeutics' EBIT stood at -$12.5 million in 2022, then sank by 50.81% to -$18.8 million in 2023, then surged by 54.3% to -$8.6 million in 2024, then fell by 8.35% to -$9.3 million in 2025, then decreased by 13.26% to -$10.6 million in 2026.
- Business Quant data shows ANTX's EBIT at -$10.6 million in Q1 2026, -$9.3 million in Q4 2025, and -$10.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | -8.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.90 Mn |
| Mar 31, 2026 | -10.55 Mn |
| Dec 31, 2025 | -9.32 Mn |
| Sep 30, 2025 | -10.04 Mn |
| Jun 30, 2025 | -7.22 Mn |
| Mar 31, 2025 | -11.54 Mn |
| Dec 31, 2024 | -8.60 Mn |
| Sep 30, 2024 | -14.01 Mn |
| Jun 30, 2024 | -15.88 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Dec 31, 2023 | -18.82 Mn |
| Sep 30, 2023 | -18.18 Mn |
| Jun 30, 2023 | -16.60 Mn |
| Mar 31, 2023 | -16.04 Mn |
| Dec 31, 2022 | -12.48 Mn |
| Sep 30, 2022 | -11.77 Mn |
| Jun 30, 2022 | -10.33 Mn |
| Mar 31, 2022 | -7.68 Mn |
| Dec 31, 2021 | -7.59 Mn |
| Sep 30, 2021 | -6.93 Mn |